502 related articles for article (PubMed ID: 27690664)
1. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
3. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
4. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Tannir NM; Schwab G; Grünwald V
Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
7. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
8. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib use in renal cell carcinoma.
Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
[TBL] [Abstract][Full Text] [Related]
11. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
12. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
González-Larriba JL; Maroto P; Durán I; Lambea J; Flores L; Castellano D;
Expert Rev Anticancer Ther; 2017 Mar; 17(3):217-226. PubMed ID: 28105863
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib: a new treatment option for renal cell carcinoma.
Saes L; Eskens FALM
Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
[TBL] [Abstract][Full Text] [Related]
14. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
15. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
18. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
20. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]